The first dosing of the first patients in an open-label study of a ketamine could not come at the more crucial time as there still remains the high unmet need for the therapy to address suicidal ideation and ehaviour in patients with Major Depressive Disorder.
Source: investingnews.comPublished on 2021-01-15
Related news
- Seelos Therapeutics Announces Completion of Open - Label Patient Enrollment of Proof of Concept Study of SLS - 002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
- 21Vianet Wins 5A Green Data Center Ratings and Further Promotes Carbon Reduction
- Seelos Therapeutics to Present a Poster on SLS - 002 at the 2021 IASR / AFSP International Summit on Suicide Research
- FactSet to Acquire CUSIP Global Services for $1 . 925 Billion
- Bronchiolitis : Treatments Are More Expensive / Intensive , But Severity of Illness Hasnt Changed
- A look at COVID - 19 vaccinations in Canada on Friday , June 4 , 2021 | iNFOnews | Thompson - Okanagan News Source